Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisors will cast separate votes March 19 on GSK’s ICS/LABA combo for patients 12-17 and for adults 18 and older.

You may also be interested in...



Asthma Warnings Not Working Well, FDA Fears As GSK Seeks Expanded LABA Approval

LABA prescribing patterns haven’t changed despite FDA’s labeling instructions on asthma safety concerns, agency concludes.

GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim

LABA safety issues may come to haunt GlaxoSmithKline as FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will focus on the combination’s product’s safety database and whether an outcomes study is needed for approval in asthma.

GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair

Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel